Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Wants Premarin Petitions Excluded From Duramed Antitrust Suit

Executive Summary

Wyeth-Ayerst's efforts to influence regulatory decisions about conjugated estrogens via citizens' petitions are an early focus of arguments in Duramed's antitrust suit against the company.

You may also be interested in...



Cenestin Sales Force Will Promote Seasonale After Barr/Duramed Merger

Barr's oral contraceptive Seasonale will be promoted by Duramed's Cenestin sales force following a merger between the two generic/brand drug companies.

Cenestin Sales Force Will Promote Seasonale After Barr/Duramed Merger

Barr's oral contraceptive Seasonale will be promoted by Duramed's Cenestin sales force following a merger between the two generic/brand drug companies.

Duramed Cenestin And Pfizer Aricept In Pilot Study For Early Alzheimer's

Duramed is planning clinical studies of its synthetic conjugated estrogen Cenestin in combination with Pfizer/Eisai's Aricept for treatment of early Alzheimer's disease, the company said during a Feb. 28 conference call.

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel